Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy

Objective: to evaluate the pharmacoeconomic feasibility of using monoclonal antibodies or their combinations vs standard therapy in patients with mild and moderate-severe COVID-19 in order to prevent the severe course of the disease.

Material and methods. The decision tree and Markov models for calculation of costs and outcomes were used for patients with COVID-19 and post-COVID-19 syndrome, respectively. The cost-effectiveness of tixagevimab and cilgavimab was evaluated in persons ≥18 years old not vaccinated against COVID-19 with a high risk of progression to severe COVID-19. Effectiveness and safety of tixagevimab and cilgavimab combination was assessed based on TACKLE phase III study results. The quantities of life years gained (LYG) and quality-adjusted life years (QALY) were calculated. Results were compared with the wiliness-to-pay threshold measured as tripled gross domestic product per capita according the World Health Organization recommendations.

Results. Treatment of COVID-19 with tixagevimab and cilgavimab results in additional 0.2657 LIGs or 0.2255 QALYs. The cost of 1 LIG was 213,4 thousand rubles, the cost of 1 QALY was 251,5 thousand rubles. Both costs of LIG and QALY appeared to be significantly less compared to the wiliness-to-pay threshold equal to 3.09 million rubles in 2022.

Conclusion. Treatment of mild and moderate-severe COVID-19 is economically feasible and may be recommended for wide use in the Russian healthcare system.

1. Sharipova M.M., Ivkina M.V., Arkhangelskaia A.N., et al. Features of the course of COVID-19 in patients with comorbid pathology. Meditsinskiy sovet / Medical Council. 2022; 16 (6): 44–9 (in Russ.). https://doi.org/10.21518/2079-701X-2022-16-6-44-49.

2. Reilev M., Kristensen K.B., Pottegard A., et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020; 49 (5): 1468–81. https://doi.org/10.1093/ije/dyaa140.

3. Mitkovskaya N., Grigorenko E., Ruzanov D., Statkevich T. Coronavirus infection COVID-19 and comorbidity. The Science and Innovations. 2020; 7: 50–60 (in Russ.). https://doi.org/10.29235/1818-9857-2020-7-50-60.

4. Guan W.J., Ni Z.Y., Hu Y., et al.. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–20. https://doi.org/10.1056/NEJMoa2002032.

5. Temporary methodological recommendations. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 17 (14.12.2022). Available at: https://normativ.kontur.ru/document?moduleId=1&documentId=438135 (in Russ.) (accessed 20.02.2023).

6. Unified information system in the field of procurement. Available at: https://zakupki.gov.ru/ (in Russ.) (accessed 20.02.2023).

7. Cox M., Peacock T.P., Harvey W.T., et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023; 21 (2): 112–24. https://doi.org/10.1038/s41579-022-00809-7.

8. Instructions for use of the medicinal product for medical use Evusheld (LP-008665). 16.11.2022. Available at: https://grls.rosminzdrav.ru/grls.aspx (in Russ.) (accessed 20.02.2023).

9. Montgomery H., Hobbs F.D.R., Padilla F., et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022; 10 (10): 985–96. https://doi.org/10.1016/S2213-2600(22)00180-1.

10. Letter of the Ministry of Health of the RF of 26.01.2023 No. 31-2/I/2-1075 “On methodological recommendations on ways to pay for medical care at the expense of compulsory medical insurance”. Available at: https://legalacts.ru/doc/pismo-minzdrava-rossii-ot-26012023-n-31-2i2-1075-o-metodicheskikh/ (in Russ.) (accessed 20.02.2023).

11. Zhuravleva M.V., Tereshchenko S.N., Zhirov I.V., et al. Сost-effectiveness of preventing cardiovascular death and achieving the target indicator “Reduction of the cardiovascular mortality of the population” of the State Program “Health Development” when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology. 2023; 28 (3): 5386 (in Russ.). https://doi.org/10.15829/1560-4071-2023-5386.

12. Life expectancy at birth in the subjects of the Russian Federation for 2022 (preliminary estimate). Available at: https://rosstat.gov.ru/storage/mediabank/ozhid_life_pr_2022.xlsx (in Russ.) (accessed 20.02.2023).

13. Population of the Russian Federation by gender and age. Available at: https://rosstat.gov.ru/compendium/document/13284 (in Russ.) (accessed 20.02.2023).

14. Decree of the Government of the RF of 29.12.2022 No. 2497 “On the Program of state guarantees of free medical care to citizens for 2023 and for the planning period of 2024 and 2025”. Available at: https://base.garant.ru/406065459/ (in Russ.) (accessed 20.02.2023).

15. State Register of Medicines. Available at: https://grls.rosminzdrav.ru/default.aspx (in Russ.) (accessed 20.02.2023).

16. Sullivan P.W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26 (4): 410–20. https://doi.org/10.1177/0272989X06290495.

17. Sheinson D., Dang J., Shah A., et al. A cost-effectiveness framework for COVID-19 treatments for hospitalised patients in the United States. Adv Ther. 2021; 38 (4): 1811–31. https://doi.org/10.1007/s12325-021-01654-5.

18. Yagudina R.I., Kulikov A.Yu., Nguyen T. Place of threshold willingness-to-pay of Russia among those of other European countries and CIS countries. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2011; 4 (1): 129 (in Russ.).

19. Teptsova T.S., Musina N.Z., Omelyanovsky V.V. Evaluation of the reference value of the incremental parameter “cost-effectiveness” for Russian healthcare system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 367–76 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.071.

20. Federal State Statistics Service. GDP per capita. Available at: https://rosstat.gov.ru/statistics/accounts (in Russ.) (accessed 20.02.2023).

21. Order of the Goverement of the RF of 15.09.2022 No. 2635-р. Available at: http://publication.pravo.gov.ru/Document/View/0001202209160030 (assessed 16.06.2023).